Subscribe for great stories in your community!
Later this week, the U.S. Food and Drug Administration is expected to make a decision on Madrigal Pharmaceuticals’ experimental NASH treatment, writes John George…
Conshohocken-based Madrigal Pharmaceuticals plans to raise $500 million while anticipating FDA approval of a groundbreaking therapy, writes John George for the Philadelphia Business Journal…
Before we send you to this site, please subscribe to our daily newsletter.